vs
Amarin Corp plc（AMRN）与Dominari Holdings Inc.（DOMH）财务数据对比。点击上方公司名可切换其他公司
Amarin Corp plc的季度营收约是Dominari Holdings Inc.的1.5倍（$45.1M vs $30.1M），Amarin Corp plc净利率更高（-23.3% vs -438.1%，领先414.8%），Dominari Holdings Inc.同比增速更快（220.4% vs 7.0%），过去两年Dominari Holdings Inc.的营收复合增速更高（369.1% vs -18.3%）
Amarin是一家1993年成立的爱裔美籍生物制药企业，总部分别设于爱尔兰都柏林与美国新泽西州布里奇沃特。该企业专注研发及销售心血管疾病治疗药物，已推出处方级Omega-3脂肪酸药物Vascepa（AMR-101）。
AMRN vs DOMH — 直观对比
营收规模更大
AMRN
是对方的1.5倍
$30.1M
营收增速更快
DOMH
高出213.4%
7.0%
净利率更高
AMRN
高出414.8%
-438.1%
两年增速更快
DOMH
近两年复合增速
-18.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $45.1M | $30.1M |
| 净利润 | $-10.5M | $-131.8M |
| 毛利率 | — | — |
| 营业利润率 | 35.5% | -8.9% |
| 净利率 | -23.3% | -438.1% |
| 营收同比 | 7.0% | 220.4% |
| 净利润同比 | 33.0% | -12426.2% |
| 每股收益（稀释后） | — | $-6.94 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMRNDOMH
| Q1 26 | $45.1M | — | ||
| Q4 25 | $49.2M | $30.1M | ||
| Q3 25 | $49.7M | $50.8M | ||
| Q2 25 | $72.7M | $34.1M | ||
| Q1 25 | $42.0M | $8.1M | ||
| Q4 24 | $62.3M | $9.4M | ||
| Q3 24 | $42.3M | $4.0M | ||
| Q2 24 | $67.5M | $6.2M |
净利润AMRNDOMH
| Q1 26 | $-10.5M | — | ||
| Q4 25 | $-1.2M | $-131.8M | ||
| Q3 25 | $-7.7M | $125.2M | ||
| Q2 25 | $-14.1M | $16.6M | ||
| Q1 25 | $-15.7M | $-32.5M | ||
| Q4 24 | $-48.6M | $1.1M | ||
| Q3 24 | $-25.1M | $-4.2M | ||
| Q2 24 | $1.5M | $-6.1M |
毛利率AMRNDOMH
| Q1 26 | — | — | ||
| Q4 25 | 47.1% | — | ||
| Q3 25 | 44.7% | — | ||
| Q2 25 | 69.2% | — | ||
| Q1 25 | 59.8% | — | ||
| Q4 24 | -15.4% | — | ||
| Q3 24 | 38.5% | — | ||
| Q2 24 | 63.4% | — |
营业利润率AMRNDOMH
| Q1 26 | 35.5% | — | ||
| Q4 25 | -12.9% | -8.9% | ||
| Q3 25 | -22.4% | -3.1% | ||
| Q2 25 | -22.0% | -57.0% | ||
| Q1 25 | -39.9% | -394.6% | ||
| Q4 24 | -84.3% | 0.4% | ||
| Q3 24 | -59.5% | -79.1% | ||
| Q2 24 | -0.8% | -44.3% |
净利率AMRNDOMH
| Q1 26 | -23.3% | — | ||
| Q4 25 | -2.5% | -438.1% | ||
| Q3 25 | -15.6% | 246.4% | ||
| Q2 25 | -19.4% | 48.7% | ||
| Q1 25 | -37.4% | -400.5% | ||
| Q4 24 | -78.0% | 11.4% | ||
| Q3 24 | -59.4% | -104.2% | ||
| Q2 24 | 2.3% | -99.1% |
每股收益（稀释后）AMRNDOMH
| Q1 26 | — | — | ||
| Q4 25 | $0.00 | $-6.94 | ||
| Q3 25 | $-0.02 | $7.27 | ||
| Q2 25 | $-0.03 | $1.12 | ||
| Q1 25 | $-0.04 | $-3.02 | ||
| Q4 24 | $-0.12 | $0.21 | ||
| Q3 24 | $-0.06 | $-0.67 | ||
| Q2 24 | $0.00 | $-1.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $307.8M | $80.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $69.4M |
| 总资产 | $645.8M | $112.9M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AMRNDOMH
| Q1 26 | $307.8M | — | ||
| Q4 25 | $302.6M | $80.5M | ||
| Q3 25 | $286.6M | $176.2M | ||
| Q2 25 | $298.7M | $28.2M | ||
| Q1 25 | $281.8M | $18.9M | ||
| Q4 24 | $294.2M | $8.2M | ||
| Q3 24 | $305.7M | $7.2M | ||
| Q2 24 | $306.7M | $12.1M |
股东权益AMRNDOMH
| Q1 26 | — | — | ||
| Q4 25 | $459.3M | $69.4M | ||
| Q3 25 | $458.9M | $210.2M | ||
| Q2 25 | $464.9M | $88.6M | ||
| Q1 25 | $473.7M | $42.4M | ||
| Q4 24 | $486.2M | $39.9M | ||
| Q3 24 | $531.4M | $38.3M | ||
| Q2 24 | $551.9M | $42.4M |
总资产AMRNDOMH
| Q1 26 | $645.8M | — | ||
| Q4 25 | $670.8M | $112.9M | ||
| Q3 25 | $659.8M | $223.4M | ||
| Q2 25 | $670.1M | $109.3M | ||
| Q1 25 | $655.7M | $52.3M | ||
| Q4 24 | $685.3M | $47.1M | ||
| Q3 24 | $750.6M | $43.4M | ||
| Q2 24 | $799.9M | $49.1M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $22.7M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流AMRNDOMH
| Q1 26 | — | — | ||
| Q4 25 | $15.3M | $22.7M | ||
| Q3 25 | $-12.7M | $-4.9M | ||
| Q2 25 | $16.6M | $-353.0K | ||
| Q1 25 | $-12.5M | $1.2M | ||
| Q4 24 | $-13.3M | $-16.7M | ||
| Q3 24 | $-2.4M | $-4.7M | ||
| Q2 24 | $-2.7M | $1.4M |
现金转化率AMRNDOMH
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | -0.04× | ||
| Q2 25 | — | -0.02× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -15.65× | ||
| Q3 24 | — | — | ||
| Q2 24 | -1.81× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMRN
| U.S | $35.6M | 79% |
| Europe | $4.9M | 11% |
| Rest-of-World (ROW) | $2.8M | 6% |
| Licensing & Royalties | $1.8M | 4% |
DOMH
| Chief Operating Decision Maker | $30.1M | 100% |
| Commissions | $458.0K | 2% |
